Greenwich LifeSciences (NASDAQ:GLSI) Issues Quarterly Earnings Results, Misses Estimates By $0.34 EPS

Greenwich LifeSciences (NASDAQ:GLSI) announced its earnings results on Monday. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.34), FiscalAI reports.

Greenwich LifeSciences Price Performance

GLSI stock traded up $2.34 during trading hours on Monday, reaching $28.51. The stock had a trading volume of 215,780 shares, compared to its average volume of 273,670. The stock has a market capitalization of $394.86 million, a PE ratio of -19.53 and a beta of 1.40. The stock has a 50-day simple moving average of $24.98 and a 200 day simple moving average of $21.90. Greenwich LifeSciences has a fifty-two week low of $7.78 and a fifty-two week high of $34.10.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Friday, May 15th. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $47.50.

Institutional Trading of Greenwich LifeSciences

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its position in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after acquiring an additional 1,322 shares during the period. Wells Fargo & Company MN increased its position in Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after acquiring an additional 4,102 shares during the period. Rhumbline Advisers increased its position in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after acquiring an additional 3,168 shares during the period. Jane Street Group LLC bought a new position in Greenwich LifeSciences during the fourth quarter worth about $203,000. Finally, Barclays PLC increased its position in Greenwich LifeSciences by 11.8% during the fourth quarter. Barclays PLC now owns 9,744 shares of the company’s stock worth $205,000 after acquiring an additional 1,030 shares during the period. Institutional investors and hedge funds own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.